Protalix BioTherapeutics Inc (PLX)
1.15
+0.01
(+0.88%)
USD |
NYAM |
May 08, 16:00
1.15
0.00 (0.00%)
After-Hours: 17:03
Protalix BioTherapeutics Accounts Receivable (Quarterly): 5.272M for Dec. 31, 2023
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 5.272M |
September 30, 2023 | 8.935M |
June 30, 2023 | 4.049M |
March 31, 2023 | 1.304M |
December 31, 2022 | 4.586M |
September 30, 2022 | 8.651M |
June 30, 2022 | 2.022M |
March 31, 2022 | 5.908M |
December 31, 2021 | 3.442M |
September 30, 2021 | 5.561M |
June 30, 2021 | 2.33M |
March 31, 2021 | 4.599M |
December 31, 2020 | 2.00M |
September 30, 2020 | 3.146M |
June 30, 2020 | 5.262M |
March 31, 2020 | 8.876M |
December 31, 2019 | 4.70M |
September 30, 2019 | 8.716M |
June 30, 2019 | 7.256M |
March 31, 2019 | 8.565M |
December 31, 2018 | 4.729M |
September 30, 2018 | 4.894M |
June 30, 2018 | 5.248M |
March 31, 2018 | 4.756M |
December 31, 2017 | 1.721M |
Date | Value |
---|---|
September 30, 2017 | 7.292M |
June 30, 2017 | 3.005M |
March 31, 2017 | 2.737M |
December 31, 2016 | 0.693M |
September 30, 2016 | 2.096M |
June 30, 2016 | 1.493M |
March 31, 2016 | |
December 31, 2015 | |
September 30, 2015 | 4.573M |
June 30, 2015 | 1.936M |
March 31, 2015 | 1.816M |
December 31, 2014 | |
September 30, 2014 | 1.992M |
June 30, 2014 | 2.097M |
March 31, 2014 | 1.735M |
December 31, 2013 | 2.091M |
September 30, 2013 | 2.053M |
June 30, 2013 | 2.03M |
March 31, 2013 | 1.698M |
December 31, 2012 | 1.41M |
September 30, 2012 | 7.306M |
June 30, 2012 | 1.536M |
March 31, 2012 | 0.815M |
December 31, 2011 | 1.374M |
September 30, 2011 | 5.291M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
1.304M
Minimum
Mar 2023
8.935M
Maximum
Sep 2023
5.085M
Average
4.70M
Median
Dec 2019
Accounts Receivable (Quarterly) Benchmarks
Agenus Inc | 25.84M |
InfuSystems Holdings Inc | 19.83M |
AIM ImmunoTech Inc | -- |
Perspective Therapeutics Inc | 1.165M |
Armata Pharmaceuticals Inc | -- |